Estimating the national cost of treating people with HIV disease: Patient, payer, and provider data

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 2, 2000, Pages 182-188

  Hellinger, Fred J ^a   Fleishman, John A ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Estimating; HIV disease; Treatment cost

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; HEALTH INSURANCE; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

EID: 0034209814     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200006010-00016     Document Type: Article

References (28)

1. U.S. Centers for Disease Control and Prevention (CDC). HIV/ AIDS surveillance report: US HIV and AIDS cases reported through June 1997, vol. 9, no. 1. Atlanta: CDC, 1997.
2. U.S. General Accounting Office. HIV/AIDS drugs: funding implications of new combination therapies for federal and state programs (GAO/HEHS-99-2). Washington DC: U.S. Government Printing Office, 1998.
3. Foster S, Gregory A, Niederhausen P, Rapallo D, Westmoreland T. Federal HIV/AIDS spending: a budget chartbook. Report prepared by the Federal Legislative Clinic at the Georgetown University Law Center. Washington DC: Henry J. Kaiser Family Foundation, 1998.
4. Hellinger FJ. Cost and financing of care for persons with HIV disease: an overview. Health Care Financ Rev 1998;19:5-18.
5. U.S. Department of Health and Human Services, Office of Inspector General. Medicaid, managed care and HIV/AIDS (OEI-05-97-00210). Washington DC: U.S. Government Printing Office, 1998.
6. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration JAMA 1998;280:1497-1503.
7. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
8. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-908.
9. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997;336:1531-2.
10. U.S. Centers for Disease Control and Prevention (CDC), National Center for HIV, STD, and TB Prevention, Division of STD Prevention. The challenge of STD in the United States. Atlanta: CDC, 1996.
11. U.S. Centers for Disease Control and Prevention (CDC). HIV/ AIDS surveillance report: US HIV and AIDS cases reported through December 1998, vol. 10, no. 2. Atlanta: CDC, 1999.
12. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998;339:1987-8.
13. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987;102:5-17.
14. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 1992;29:356-65.
15. Hellinger FJ. Forecasting the medical care costs of the HIV epidemic: 1991-1994. Inquiry 1991;28:213-25.
16. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a veterans administration hospital. JAIDS J Acquir Immune Defic Syndr 1999;20:28-33.
17. Gerson V. How business is dealing with the AIDS epidemic. Business Health 1997;15:17-20.
18. Levit KR, Lazenby HC, Braden BR, et al. National health expenditures, 1996. Health Care Financ Rev 1997;19:161-200.
19. Philadelphia Commission on AIDS: report to the community. Philadelphia, PA: Pew Charitable Trusts, 1988.
20. Fasciano NJ, Cherlow AL, Turner B, Thornton CV. Profile of Medicare beneficiaries with AIDS: application of AIDS casefinding algorithm. Health Care Financ Rev 1998;19:19-38.
21. U.S. Department of Commerce. State and metropolitan area data book, 1997-98. Washington DC: U.S. Government Printing Office, 1998.
22. U.S. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: US HIV and AIDS cases reported through December 1996, vol. 8, no. 2. Atlanta: CDC, 1997.
23. Muirhead G. Double digits: managed care drives Rx sales to new levels: IMS America Ltd. Statistics for 1996 drug sales. Drug Topics 1997;141:99-103.
24. Cohen J. The marketplace of HIV/AIDS. Science 1996;272: 1880-1.
25. Elcock M, Simon T, Gilbert BP. Active AIDS surveillance: hospital-based case in a metropolitan California county. Am J Public Health 1993;83:1002-5.
26. Rosenblum L, Buehler JW, Morgan MW, et al. HIV infection in hospitalized patients and Medicaid enrollees: the accuracy of medical record coding. Am J Public Health 1993;83:1457-9.
27. Fleishman JA. Transitions in insurance and employment among people with HIV infection. Inquiry 1998;35:36-48.
28. HIV therapy audit only projectable database of patients seeking treatment. AIDS Wkly Plus 1997;July 28:4.